More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.09B
EPS
-0.75
P/E ratio
--
Price to sales
3.99
Dividend yield
--
Beta
0.17404
Previous close
$30.12
Today's open
$29.65
Day's range
$29 - $30.39
52 week range
$25.76 - $54.85
show more
CEO
Mark L. Baum
Employees
373
Headquarters
Nashville, TN
Exchange
NASDAQ Global Market
Shares outstanding
37533160
Issue type
Common Stock
Healthcare
Pharmaceuticals
Harrow: Strong Revenue Growth And Operating Leverage Ahead
Harrow Inc. is positioned to achieve its ambitious $350MM 2026 revenue target after strong Q3 execution. VEVYE and IHEEZO delivered robust sequential growth, with VEVYE up 35% and IHEEZO up 62% quarter-over-quarter. Expanded commercial coverage and a larger sales team are driving improved VEVYE ASP and market share gains.
Seeking Alpha • Nov 16, 2026

Harrow to Participate in Two Investor Conferences in November
NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following investor conferences in November: Craig-Hallum 17 th Annual Alpha Select Conference Format: 1x1 investor meetings Date: Tuesday, November 17, 2026 Location: New York, NY 2026 Jefferies Global Healthcare Conference Format: Presentation and 1x1 investor meetings Date/Time: Wednesday, November 18, 2026 at 8:00 a.m.
GlobeNewsWire • Nov 12, 2026

Harrow Q3 Earnings Call Highlights
Harrow NASDAQ: HROW reported record third-quarter revenue and reaffirmed its full-year sales forecast, but sharply reduced its adjusted earnings outlook as lower-than-expected margins and accelerated spending weighed on profitability.
MarketBeat • Nov 10, 2026

Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript
Harrow, Inc. ( HROW ) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the Board & Founder Andrew Boll - President, CFO & Chief Accounting Officer Patrick Sullivan - Chief Commercial Officer Amir Shojaei - Chief Scientific Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Thomas Shrader - BTIG, LLC, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Mayank Mamtani - B.
Seeking Alpha • Nov 10, 2026

Harrow Announces Third Quarter 2026 Financial Results
Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and approximately 84% of total revenue GAAP net income of $9.8 million, including a $5.0 million litigation settlement gain, compared with a net loss of $17.3 million in the second quarter of 2026 and net income of $1.0 million in the third quarter of 2025 Adjusted EBITDA (a non-GAAP measure) of $21.2 million, compared with $(1.2) million in the second quarter of 2026 and $22.8 million in the third quarter of 2025 Reaffirmed full-year 2026 revenue guidance of $350 million to $365 million; updated full-year 2026 Adjusted EBITDA guidance to more than $40 million, including fourth quarter Adjusted EBITDA of more than $33 million, compared with prior Adjusted EBITDA guidance of $80 million to $100 million Cash and cash equivalents of $75.3 million as of September 30, 2026 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.
GlobeNewsWire • Nov 9, 2026

Harrow (HROW) Q3 Earnings Lag Estimates
Harrow (HROW) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.33 per share a year ago.
Zacks Investment Research • Nov 10, 2026

Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 10, 2026

Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?
Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Nov 2, 2026

Harrow Launches HarrowRx Platform
NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access pharmacy platform that enables eyecare professionals to access Harrow's entire portfolio directly within the electronic medical record (EMR) systems they already use.
GlobeNewsWire • Nov 2, 2026

PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow's Eye Care Portfolio
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, to launch HarrowRx, Harrow's new prescribing and access platform. HarrowRx gives eye care providers the ability to e-prescribe Harrow's branded ophthalmic portfolio from one destination within the electronic medical record (EMR) systems they already use, with built.
Business Wire • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Harrow Inc Com commission-free¹. Build wealth for the long term using automated trading and transfers.